Capabilities
Our Digital Health group guides companies through the myriad considerations they encounter as the delivery of healthcare becomes increasingly digital.
As private equity investment in the Life Sciences and Healthcare industry continues to increase, our cohesive regulatory and transactional approach helps ensure success through each phase of investment.
We provide 360-degree support to companies that develop, manufacture and distribute products tailored specifically toward improving women’s health, from start-ups to global corporations.
Our Sunshine and State Law Compliance Group serves as a powerful industry advocate with respect to transparency laws for more than 100 members companies.
We established the Surprise Billing and Price Transparency Group to assist our clients in developing solutions to changes in healthcare transparency laws.
The K&S International Ad Hoc Group is a coalition of 20+ pharma and medical device companies that focuses on international transparency/disclosure laws targeting manufacturers.
February 9, 2026
FTC’s “Landmark” Settlement with Pharmacy Benefit Manager Express Scripts: Impact on Pharma
January 21, 2026
2025 Year in Review: FDA Drug and Device Advertising and Promotion Enforcement
December 30, 2025
The One Big Beautiful Bill Act Explained: A Detailed Review of Key Changes for the Health Care Industry
February 12, 2026
Chambers Global 2026 Recognizes King & Spalding as a Leading International Law Firm
February 9, 2026
CVN Ranks King & Spalding’s Terumo Trial Victory as the #1 Most Impressive Defense Verdict of 2025
February 9, 2026
First-Chair Trial Lawyer and Former Federal Prosecutor Tinos Diamantatos Joins King & Spalding in Chicago
January 27, 2026
King & Spalding Secures Significant Success for R.J. Reynolds
November 25, 2025
King & Spalding Secures Another Victory for Boehringer Ingelheim in Zantac-Related Trial
October 10, 2025
King & Spalding Secures Significant Victory for R.J. Reynolds